Resistance to Proteasome Inhibitors in Cancer Molecular Mechanisms and Strategies to Overcome Resistance /

The book explores cutting-edge strategies to overcome proteasome inhibitor resistance, including the second generation 20S proteasome inhibitors, novel combinational therapies, and new targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3 ligases, deubiquitinases, 19S proteasomal ATPases,...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Dou, Q. Ping (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2014.
Σειρά:Resistance to Targeted Anti-Cancer Therapeutics,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
Πίνακας περιεχομένων:
  • Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer
  • Resistance to proteasome inhibitors in multiple myeloma
  • Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma
  • Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis
  • Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy
  • Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition
  • Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies
  • Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches
  • Targeting the proteasome pathway for the treatment of solid tumors
  • Oxidative stress and the proteasome: mechanism and the therapeutic relevance
  • Proteotoxic stress and proteasome inhibitor efficacy and resistance
  • Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy
  • Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2)
  • The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies
  • Deubiquitinating enzymes as novel targets for cancer therapies.